| Symbol
| WNT5A
| contributors: shn/ - updated : 27-01-2016
|
| HGNC name
| wingless-type MMTV integration site family, member 5A
|
| HGNC id
| 12784
|
| corresponding disease(s)
|
RBNS2
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --low
|
|
aberrantly methylated from the early stages of colorectal cancers  | | tumoral
|
|
|
| loss of function
| |
inactivated by aberrant methylation in acute lymphoblastic leukaemia | | tumoral
|
|
| --over
|
| |
by hypomethylation in prostate cancer | | tumoral
|
|
| --low
|
| |
in epithelial ovarian cancer | | tumoral
|
|
| --over
|
| |
in melanoma and is thought to be a critical regulator of cell movement during metastasis | |
Variant & Polymorphism
| 
| |
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | | | |
| WNT5A-ROR2 signaling can be a target of cancer therapies to prevent cancer cells from undergoing invasion and metastasis
| | cancer | reproductive | ovary | |
| by reconstituting WNT5A signaling may offer an effective new strategy for EOC therapy |
| | | |
|
| Wnt5a-/- mice exhibit dwarfism, facial abnormalities, short limbs and tails, dysplasia of lungs and genitals, and ventricular septal defects | |
Wnt5a-/- mice display a defect in (mid)brain morphogenesis, including an impairment in midbrain elongation and a rounded ventricular cavity |